RxDoctor Payments Data

Megan Webb

Family · Raleigh, NCNPI 1447843669

Payments from drug & device makers

$1,956in general payments, 2019–2025

Across 87 payments — averaging $22.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Scilex Pharmaceuticals Inc.$582
  • Braeburn Inc.$332
  • Forte Bio-pharma LLC$289
  • Indivior Inc.$259
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$199
  • Valinor Pharma, LLC$72
  • plus $224 from 6 others

What the payments were for

  • Food & beverage$1,956100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,956 in reported general payments places this provider in the 80th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$61,128
Medicare patients
101
Services billed
526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate127$103,051
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen394$91,724
ZtlidoLidocaine53$53,735
OxycontinOxycodone Hcl76$50,878
SublocadeBuprenorphine25$50,617
RelistorMethylnaltrexone Bromide21$50,428
ProlateOxycodone Hcl/Acetaminophen11$36,972
MovantikNaloxegol Oxalate71$34,930
Buprenorphine51$17,257
Lidocaine89$17,229
LinzessLinaclotide23$16,508
NucyntaTapentadol Hcl16$10,893
Diclofenac Sodium72$10,269
ButransBuprenorphine19$9,850
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl56$9,509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta$54$113,944143 claims
Scilex Pharmaceuticals Inc.Ztlido$582$53,73553 claims
Indivior Inc.Sublocade$259$50,61725 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$199$50,42821 claims
Forte Bio-pharma LLCProlate$289$36,97211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,522 family providers in North Carolina.

Other family in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →